| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 59651-0465-29 | 59651-0465 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 75907-0405-30 | 75907-0405 | Bosutinib | Bosutinib | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 12, 2026 | In Use | |
| 59651-0532-10 | 59651-0532 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
| 59651-0545-30 | 59651-0545 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 60687-0882-21 | 60687-0882 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 19, 2025 | In Use | |
| 16714-0676-01 | 16714-0676 | Sunitinib malate | Sunitinib malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Feb 18, 2022 | Sep 30, 2026 | In Use |
| 13668-0735-90 | 13668-0735 | Pazopanib hydrochloride | Pazopanib | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Sep 4, 2025 | In Use | |
| 60505-4779-05 | 60505-4779 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Oct 19, 2023 | In Use | |
| 31722-0780-33 | 31722-0780 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 68382-0244-16 | 68382-0244 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 81927-0201-01 | 81927-0201 | Imatinib oral | IMKELDI | 80.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 19, 2024 | In Use | |
| 43598-0603-30 | 43598-0603 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 70771-1904-03 | 70771-1904 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 00078-0649-30 | 00078-0649 | Imatinib Mesylate | Gleevec | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 23, 2014 | Dec 31, 2026 | In Use |
| 69539-0091-30 | 69539-0091 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 00003-0855-22 | 00003-0855 | Dasatinib | Sprycel | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 28, 2010 | In Use | |
| 70771-1522-03 | 70771-1522 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 42388-0024-46 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 9, 2023 | In Use | |
| 62856-0724-30 | 62856-0724 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 51144-0002-60 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use | |
| 46708-0565-90 | 46708-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 64679-0793-01 | 64679-0793 | imatinib mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
| 45629-0089-01 | 45629-0089 | Tivozanib | FOTIVDA | 0.89 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Mar 10, 2021 | In Use | |
| 72579-0122-01 | 72579-0122 | Zanubrutinib | BRUKINSA | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Aug 18, 2025 | In Use | |
| 57894-0080-60 | 57894-0080 | Lazertinib | LAZCLUZE | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 20, 2024 | In Use |
Found 12482 results — Export these results
Home